表柔比星与多柔比星的心脏毒性：成本与临床结果。 - Suppr | 超能文献

Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.

作者信息

Ventura Gerard J

出版信息

J Clin Oncol. 2005 Apr 20;23(12):2873; author reply 2873-4. doi: 10.1200/JCO.2005.05.332.

DOI:10.1200/JCO.2005.05.332

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.表柔比星与多柔比星的心脏毒性：成本与临床结果。

J Clin Oncol. 2005 Apr 20;23(12):2873; author reply 2873-4. doi: 10.1200/JCO.2005.05.332.

2

Liposomal doxorubicin in breast cancer: new preparation. Much ado about nothing.脂质体阿霉素在乳腺癌治疗中的应用：新制剂。小题大做。

Prescrire Int. 2003 Jun;12(65):93-5.

3

Doxorubicin liposomal pegylated: new preparation. Breast cancer: not just a question of short-term cardiac effects.聚乙二醇化脂质体阿霉素：新制剂。乳腺癌：不仅仅是短期心脏效应的问题。

Prescrire Int. 2004 Jun;13(71):90-1.

4

New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.表柔比星心脏毒性的新见解：1097例乳腺癌患者的竞争风险分析

J Natl Cancer Inst. 2008 Aug 6;100(15):1058-67. doi: 10.1093/jnci/djn206. Epub 2008 Jul 29.

5

Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.在接受多柔比星或表柔比星化疗治疗癌症的患者中使用右丙亚胺作为心脏保护剂。省级系统治疗疾病部位组。

Cancer Prev Control. 1999 Apr;3(2):145-59.

6

Cardiotoxicity in patients treated with bevacizumab is potentially reversible.接受贝伐单抗治疗的患者发生的心脏毒性可能是可逆的。

J Clin Oncol. 2011 Jun 20;29(18):e560-2. doi: 10.1200/JCO.2011.35.5008. Epub 2011 May 23.

7

[Cancer of the breast in young women: should chemotherapy be intensified?].[年轻女性乳腺癌：化疗应强化吗？]

Pathol Biol (Paris). 1992 Nov;39(9):843-4.

8

A case of manic episode during treatment with 5-fluorouracil, epirubicin and cyclophosphamide for breast cancer.1例乳腺癌患者在接受5-氟尿嘧啶、表柔比星和环磷酰胺治疗期间出现躁狂发作。

Gen Hosp Psychiatry. 2007 Sep-Oct;29(5):461-3. doi: 10.1016/j.genhosppsych.2007.04.007.

9

Anthracycline cardiotoxicity: one size does not fit all!蒽环类药物心脏毒性：并非一概而论！

J Natl Cancer Inst. 2008 Aug 6;100(15):1046-7. doi: 10.1093/jnci/djn241. Epub 2008 Jul 29.

10

Amelioration of doxorubicin cardiotoxicity by the bispiperazinedione ICRF-187 in women with advanced breast cancer: a preliminary report.双哌嗪二酮ICRF-187改善晚期乳腺癌女性患者阿霉素心脏毒性的初步报告。

Neoplasma. 1993;40(4):259-62.

引用本文的文献

1

The Employment of Genera , , and Polyphenols for the Reduction of Selected Anti-Cancer Drug Side Effects.使用属、多酚来减少特定抗癌药物的副作用。

Nutrients. 2022 Apr 10;14(8):1574. doi: 10.3390/nu14081574.

2

Different anthracycline derivates for reducing cardiotoxicity in cancer patients.用于降低癌症患者心脏毒性的不同蒽环类衍生物。

Cochrane Database Syst Rev. 2010 May 12;2010(5):CD005006. doi: 10.1002/14651858.CD005006.pub4.